Inclusion Criteria:

- Capable of giving signed informed consent, which includes compliance with the
requirements and restrictions listed in the informed consent form (ICF) and in this
protocol.

- Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of
consent for participation in investigational clinical studies) at the time of signing
the informed consent.

- Contraceptive use by men and women should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

- Adequate organ and marrow function

Exclusion Criteria:

- History of trauma or major surgery within 28 days prior to the first dose of study
treatment.

- Prior treatment with an anti-TIGIT antibody.

- Any active or prior autoimmune disease that required treatment within 3 years of the
first dose of study treatment.

- Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic
agents, or use of other investigational drugs within 28 days before first dose of
study treatment.

- Discontinued prior immunotherapy for immune related adverse events with a high
severity.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/15/22. Questions regarding updates should be directed to the study team contact.